CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced it has granted equity inducement awards to 17 new non-executive employees under the company’s 2025 Inducement Plan.
Approved by the independent Compensation Committee, the awards were made in accordance with Nasdaq listing requirements as part of employment agreements. In total, the new hires received 4,510 time-based restricted stock units, which will vest in four equal installments over four years, contingent on continued employment.
Madrigal is focused on therapies for metabolic dysfunction-associated steatohepatitis (MASH). Its lead therapy, Rezdiffra (resmetirom), is the first drug approved by both the FDA and European Commission for MASH with moderate to advanced fibrosis. A Phase 3 outcomes trial is underway to assess the treatment’s potential in patients with compensated MASH cirrhosis.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.